201 completed, 78 unknown, 34 terminated, 9 withdrawn. 212 Phase 2, 68 Phase 1, 63 Phase 3, 14 Not applicable, 7 Phase 4.
Follow Gefitinib: new trials by email Literature Review of Gefitinib trials Research Report on Gefitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer Lenvatinib, Tislelizumab, Gefitinib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 120 | 2026-11-01 | 2026-09-21 |
| Therapy for Advanced NSCLC With EGFR 19delins Mutation Icotinib/Gefitinib - Lung Cancer | Early Phase 1 | Not yet recruiting | Fuzhou General Hospital | 94 | 2026-03-30 | 2026-03-09 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases New use of osimertinib, New use of erlotinib or gefitinib - Non Small Cell Lung Cancer | Completed | Brigham and Women's Hospital | 4864 | 2024-10-30 | 2026-01-30 | |
| A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET sorafenib, gefitinib - Pancreatic Neuroendocrine Neoplasm, Sorafenib | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 20 | 2024-09-30 | 2025-01-10 | |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients BPI-7711, Gefitinib, Placebo Tablet - NSCLC | Phase 3 | Unknown | Beta Pharma Shanghai | 369 | 2021-04-30 | 2024-08-07 |
| Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma Lenvatinib and Gefitinib - Hepatocellular Carcinoma, Molecular Targeted Therapy | Not applicable | Completed | RenJi Hospital | 30 | 2020-12-02 | 2023-08-01 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study Bevacizumab, Erlotinib, Gefitinib - NSCLC | Unknown | Guangdong Association of Clinical Trials | 272 | 2020-10-07 | 2020-10-20 | |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study PD-1 inhibitor, Chemotherapy Drugs, Cancer - Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | Unknown | Sungkyunkwan University | 4724 | 2020-07-01 | 2020-05-28 | |
| Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Gefitinib, Bevacizumab Combined With Gefitinib - PFS | Phase 2 | Unknown | Fudan University | 120 | 2020-06-08 | 2020-06-12 |
| Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients Apatinib Mesylate, Gefitinib - NSCLC | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 22 | 2020-05-26 | 2021-01-11 |
| Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib Gefitinib, Anlotinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Second Affiliated Hospital of Nanchang University | 240 | 2020-05-01 | 2020-04-24 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6000 | 2020-04-16 | 2024-10-22 |
| Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) Lazertinib 240 mg/160 mg, Gefitinib 250 mg, Lazertinib-matching placebo 240 mg/160 mg - Non-Small Cell Lung Cancer | Phase 3 | Completed | Yuhan Corporation | 393 | 2020-02-13 | 2026-06-29 |
| A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer SH-1028 tablets, Placebo SH-1028 tablets, Gefitinib - Non-Small Cell Lung Cancer | Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 240 | 2020-01-31 | 2020-01-27 |
| The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®) - Non-squamous, Non-Small Cell Lung Cancer | Completed | Boehringer Ingelheim | 462 | 2019-12-17 | 2023-05-25 | |
| ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC ASK120067, Placebo Gefitinib 250 mg, Gefitinib - Locally Advanced or Metastatic NSCLC | Phase 3 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 337 | 2019-07-23 | 2024-06-14 |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI Anlotinib Hydrochloride - NSCLC | Not applicable | Unknown | Guangdong Association of Clinical Trials | 120 | 2019-07-01 | 2019-07-05 |
Showing 20 of 336. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (134) · Lung Neoplasms (50) · Breast Neoplasms (24) · Head and Neck Neoplasms (22) · Adenocarcinoma of Lung (18) · Brain Neoplasms (15) · Neoplasms (14) · Adenocarcinoma, Bronchiolo-Alveolar (11) · Squamous Cell Carcinoma of Head and Neck (10) · Colorectal Neoplasms (9) · Esophageal Neoplasms (9) · Glioblastoma (9) · Adenocarcinoma Of Esophagus (7) · Colonic Neoplasms (7) · Gliosarcoma (7)
AstraZeneca (66) · National Cancer Institute (NCI) (24) · Sun Yat-sen University (9) · Memorial Sloan Kettering Cancer Center (7) · Eli Lilly and Company (6) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Guangdong Association of Clinical Trials (5) · M.D. Anderson Cancer Center (5) · Samsung Medical Center (5) · University of Chicago (5) · Fudan University (4) · Massachusetts General Hospital (4) · National Cancer Center, Korea (4) · Novartis Pharmaceuticals (4) · Dana-Farber Cancer Institute (3)
United States (118) · China (77) · South Korea (37) · Italy (25) · Spain (24) · Taiwan (24) · France (23) · United Kingdom (23) · Germany (21) · Canada (20) · Singapore (20) · Australia (14) · Belgium (14) · Japan (14) · Netherlands (12)
David J. Adelstein, MD (3) · Mengzhao Wang, MD (3) · Aminah Jatoi, MD (2)
PMID 16204011, PMID 17075123, PMID 19692680, PMID 22333554, PMID 28212993, PMID 28958502, PMID 30017884, PMID 31439584, PMID 31751012, PMID 10811675, PMID 10856094, PMID 10999768, PMID 12748244, PMID 14570950, PMID 15117980, PMID 15659491, PMID 16014882, PMID 16061871, PMID 16062074, PMID 16110021, PMID 16179100, PMID 16257339, PMID 16361624, PMID 16549997, PMID 17026790, PMID 17161453, PMID 17216531, PMID 17330838, PMID 17563856, PMID 17694310, PMID 17985985, PMID 18096565, PMID 18300255, PMID 18448563, PMID 18577994, PMID 18779611, PMID 18779612, PMID 18845990, PMID 18981005, PMID 19027483, PMID 19060587, PMID 19288572, PMID 19574932, PMID 19581016, PMID 19692684, PMID 19704057, PMID 19879702, PMID 20022809, PMID 20035186, PMID 20038723
U10CA021115 (4), U10CA032102 (4), 2014 (3), P30CA043703 (3), U10CA031946 (3), 2004 (2), 2008 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), N01CM62205 (1), P30CA006516 (1), P30CA006973 (1)